Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
133.7 USD | +1.26% | +1.46% | +1.44% |
Apr. 17 | Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test | MT |
Apr. 16 | Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.44% | 13.44B | |
+2.49% | 96.73B | |
-0.44% | 21.31B | |
-16.61% | 21.21B | |
-5.38% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+21.29% | 10.98B | |
-21.79% | 8.56B | |
+12.82% | 8.12B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Wedbush Adjusts Price Target for Neurocrine Biosciences to $103 From $104, Maintains Outperform Rating